scholarly article | Q13442814 |
meta-analysis | Q815382 |
P356 | DOI | 10.7326/0003-4819-146-4-200702200-00007 |
P698 | PubMed publication ID | 17310052 |
P50 | author | James Douketis | Q100404477 |
P2093 | author name string | Francesco Dentali | |
Wendy Lim | |||
Mark A Crowther | |||
Monica Gianni | |||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | anticoagulation | Q63279445 |
anticoagulant | Q215118 | ||
patient | Q181600 | ||
meta-analysis | Q815382 | ||
hospitalization | Q3140971 | ||
venous thromboembolism | Q9397786 | ||
P304 | page(s) | 278-288 | |
P577 | publication date | 2007-02-01 | |
P1433 | published in | Annals of Internal Medicine | Q564416 |
P1476 | title | Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients | |
P478 | volume | 146 |
Q34677347 | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib |
Q91665729 | A Prospective Observational Cohort of Clinical Outcomes in Medical Inpatients prescribed Pharmacological Thromboprophylaxis Using Different Clinical Risk Assessment Models(COMPT RAMs) |
Q33823987 | A clinical decision support system for venous thromboembolism prophylaxis at a general hospital in a middle-income country |
Q44575292 | A simple reminder system improves venous thromboembolism prophylaxis rates and reduces thrombotic events for hospitalized patients1. |
Q95479053 | ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients |
Q33686796 | Acupuncture safety in patients receiving anticoagulants: a systematic review. |
Q38065716 | Acute pulmonary embolectomy |
Q34935712 | Addressing the sociotechnical drivers of quality improvement: a case study of post-operative DVT prophylaxis computerised decision support |
Q39920823 | Adequacy of venous thromboprophylaxis in acutely ill medical patients (IMPART): multisite comparison of different clinical decision support systems |
Q45765797 | Adherence to guideline-directed venous thromboembolism prophylaxis among medical and surgical inpatients at 33 academic medical centers in the United States |
Q59333344 | American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients |
Q33306744 | Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis |
Q33394991 | Anticoagulant utilization evaluation in a teaching hospital: a prospective study |
Q35752541 | Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
Q37302486 | Assessment of risk and prophylaxis for deep vein thrombosis and pulmonary embolism in medically ill patients during their early days of hospital stay at a tertiary care center in a developing country |
Q52655418 | Assessment of the Risk of Venous Thromboembolism in Medical Inpatients using the Padua Prediction Score and Caprini Risk Assessment Model. |
Q42141674 | Asymptomatic deep vein thrombosis in a patient with major depressive disorder |
Q37394302 | Audit of anticoagulant thromboprophylaxis in hospitalized oncology patients |
Q38004991 | Benefits versus risks of pharmacological prophylaxis to prevent symptomatic venous thromboembolism in unselected medical patients revisited. Meta-analysis of the medical literature |
Q88599305 | Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation |
Q50981591 | Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study. |
Q35766093 | Blood disorders and public health |
Q37393386 | Cancer, clots and consensus: new understanding of an old problem. |
Q40573589 | Central venous catheters and upper extremity deep vein thrombosis in medical inpatients: the Medical Inpatients and Thrombosis (MITH) Study |
Q37591970 | Characterization of Venous Thromboembolism Risk in Medical Inpatients Using Different Clinical Risk Assessment Models |
Q33392773 | Choosing the Right Heparin Prophylaxis Strategy in Medical Patients at Risk for Developing VTE: An Evidence-Based Approach |
Q38053893 | Clinical decision support systems to improve utilization of thromboprophylaxis: a review of the literature and experience with implementation of a computerized physician order entry program |
Q38537785 | Clinical development of rivaroxaban: emerging new clinical evidences? |
Q87951597 | Clinical impact of application of risk assessment models (Padua Prediction Score and Improve Bleeding Score) on venous thromboembolism, major hemorrhage and health expenditure associated with pharmacologic VTE prophylaxis: a "real life" prospective |
Q40030199 | Clinical predictors of prophylaxis use prior to the onset of acute venous thromboembolism in hospitalized patients SWIss Venous ThromboEmbolism Registry (SWIVTER). |
Q34032797 | Clinicians adopting evidence based guidelines: a case study with thromboprophylaxis |
Q38963690 | Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. |
Q36160668 | Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival |
Q43978668 | Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials |
Q55285030 | Compliance with current VTE prophylaxis guidelines and risk factors linked to complications of VTE prophylaxis in medical inpatients: a prospective cohort study in a Spanish internal medicine department. |
Q37330311 | Current issues in thromboprophylaxis in the elderly |
Q37806823 | Deep Vein Thrombosis Prophylaxis in Hospitalized Medical Patients: Current Recommendations, General Rates of Implementation, and Initiatives for Improvement |
Q37247723 | Deficits in discharge documentation in patients transferred to rehabilitation facilities on anticoagulation: results of a systemwide evaluation. |
Q37740224 | Defining the population in need of thromboprophylaxis - making hospitals safer |
Q33619196 | Designing and implementing effective venous thromboembolism prevention protocols: lessons from collaborative efforts |
Q37259975 | Development and implementation of a program to assess medical patients' need for venous thromboembolism prophylaxis |
Q36241067 | Diagnosis of abdominal mural aortic thrombus following discovery of common femoral artery and vein thrombosis by point-of-care ultrasound |
Q38052841 | Do medical patients need to receive pharmacologic prophylaxis for the prevention of venous thromboembolism? |
Q45910165 | Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis. |
Q40434706 | Effect of medical thromboprophylaxis on mortality from pulmonary embolus and major bleedingy |
Q51759037 | Effects of clinical decision support on venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital. |
Q33310985 | Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis |
Q47289396 | Electronic alert system for improving appropriate thromboprophylaxis in hospitalized medical patients: a randomized controlled trial |
Q79916550 | Electronic alerts for hospitalized high-VTE risk patients not receiving prophylaxis: a cohort study |
Q43088071 | Enhanced antithrombotic effects of unfractionated heparin in rats after repeated oral doses and its relationship to endothelial heparin concentration |
Q43063535 | Enoxaparin for the prevention of venous thromboembolism |
Q40125430 | Estimation of clinical and economic effects of prophylaxis against venous thromboembolism in medical patients, including the effect of targeting patients at high-risk |
Q33385781 | Evaluating the effectiveness of a deep-vein thrombosis prophylaxis protocol in orthopaedics and traumatology. |
Q52590558 | Evaluation and management of thromboprophylaxis in Moroccan hospitals at national level: the Avail-MoNa study. |
Q64063315 | Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment |
Q27003914 | Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? |
Q49679442 | Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis |
Q34959822 | Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol |
Q39024214 | Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials |
Q42879815 | Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs |
Q33594880 | Health and life insurance as an alternative to malpractice tort law |
Q24194750 | Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction) |
Q38264844 | Heparin-based treatment to prevent symptomatic deep venous thrombosis, pulmonary embolism or death in general medical inpatients is not supported by best evidence |
Q45977966 | High risk for venous thromboembolism in diabetics with hyperosmolar state: comparison with other acute medical illnesses. |
Q37877058 | Identification of patient venous thromboembolism risk across the continuum of care |
Q38095855 | Impact of a venous thromboembolism prophylaxis "smart order set": Improved compliance, fewer events. |
Q37630374 | Impact on patient care: patient case through the continuum of care |
Q40212061 | Improved venous thromboembolism prophylaxis by pharmacist-driven interventions in acutely ill medical patients in Belgium |
Q33166641 | Improving VTE risk assessment at point of admission to a tertiary centre cardiology ward |
Q46463571 | Improving the use of anticoagulant therapies in acutely ill medical patients |
Q48336069 | Improving venous thromboembolic disease prophylaxis in medical inpatients: a role for education and audit. |
Q43114444 | Improving venous thromboembolism risk assessment compliance using the electronic tool in admitted medical patients |
Q41198389 | Incidence and risk factors of venous thromboembolism after pelvic uro-oncologic surgery--a single center experience |
Q33504256 | Incidence rate of pulmonary embolism in Germany: data from the federal statistical office |
Q33792528 | Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients |
Q44149479 | Influence of recent immobilization or surgery on mortality in cancer patients with venous thromboembolism |
Q60931782 | KSHF Guidelines for the Management of Acute Heart Failure: Part II. Treatment of Acute Heart Failure |
Q36396598 | Lessons from the Johns Hopkins Multi-Disciplinary Venous Thromboembolism (VTE) Prevention Collaborative |
Q36393768 | Measures of risk and their relationship to the relative size of a high-risk group: application to medical thromboprophylaxis |
Q38081831 | Medical prophylaxis: the value of an "opt in" policy |
Q43018499 | Meeting the unmet needs in anticoagulant therapy |
Q36030020 | Multifaceted Intervention to Prevent Venous Thromboembolism in Patients Hospitalized for Acute Medical Illness: A Multicenter Cluster-Randomized Trial |
Q35820029 | Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis |
Q42991808 | PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. |
Q35975073 | Patient Preferences for Receiving Education on Venous Thromboembolism Prevention - A Survey of Stakeholder Organizations |
Q38161521 | Patient selection for thromboprophylaxis in medical inpatients |
Q48250305 | Patterns and outcomes of prescribing venous thromboembolism prophylaxis in hospitalized older adults: a retrospective cohort study. |
Q38915679 | Perioperative risk factors for death among patients with symptomatic pulmonary thromboembolism |
Q45745535 | Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims. |
Q33982604 | Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients |
Q33384984 | Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients |
Q47743592 | Prescriber knowledge and attitudes regarding non-administration of prescribed pharmacologic venous thromboembolism prophylaxis |
Q98719193 | Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study |
Q38315654 | Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing |
Q24633010 | Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
Q80613292 | Prevention of in-hospital VTE: why can't we do better? |
Q37038414 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma |
Q38121770 | Prevention of venous thromboembolism in acutely ill medical patients after the results of recent trials with the new oral anticoagulants |
Q33410578 | Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux |
Q33416926 | Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. |
Q37393398 | Prevention of venous thromboembolism in hospitalized patients with cancer |
Q37450787 | Prevention of venous thromboembolism in medical patients and outpatients |
Q37561377 | Prevention of venous thromboembolism: a key patient safety priority |
Q26753853 | Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review |
Q37316796 | Primary prevention of venous thromboembolism in elderly medical patients |
Q38211940 | Prophylaxis against venous thromboembolism in hospitalized medically ill patients: Update and practical approach |
Q43182364 | Prophylaxis for thromboembolism in internal medicine and family practice |
Q37799316 | Prophylaxis for venous thromboembolism: guidelines translated for the clinician |
Q82868878 | Prophylaxis of venous thromboembolism in IBD |
Q93661209 | Prophylaxis with heparin prevents pulmonary embolus in medical inpatients |
Q38079539 | Rationale supporting an "opt-out" policy for pharmacological venous thromboembolism prophylaxis in hospitalized medical patients |
Q37621561 | Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. |
Q35747987 | Risk factors for inpatient venous thromboembolism despite thromboprophylaxis |
Q37142210 | Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients |
Q50709494 | Risks, dangers and competing clinical decisions on venous thromboembolism prophylaxis in hospital care. |
Q55345178 | Sabemos prescrever profilaxia de tromboembolismo venoso nos pacientes internados? |
Q58420854 | Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study |
Q92353984 | Saudi Heart Association (SHA) guidelines for the management of heart failure |
Q33396864 | Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation |
Q38049779 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations |
Q38053889 | Statins for the prevention of venous thromboembolism? a narrative review |
Q26799392 | Steps to consider in the approach and management of critically ill patient with spontaneous intracerebral hemorrhage |
Q36541962 | Strategies to enhance venous thromboprophylaxis in hospitalized medical patients (SENTRY): a pilot cluster randomized trial. |
Q37637711 | The Saudi clinical practice guideline for the prophylaxis of venous thromboembolism in medical and critically ill patients |
Q36987388 | The impact of the DoH Commissioning for Quality and Innovation incentive on the success of venous thromboembolism risk assessment in hospitalised patients. A single institution experience in a quality outcome improvement over a 4-year cycle |
Q37348357 | The prevention of hospital-acquired venous thromboembolism in the United Kingdom |
Q44735545 | The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy |
Q91589497 | The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy |
Q34152778 | The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations |
Q38194169 | The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis. |
Q53923820 | Thromboprophylaxis adherence to the ninth edition of American college of chest physicians antithrombotic guidelines in a tertiary care centre: a cross-sectional study. |
Q42354904 | Thromboprophylaxis after hospital discharge in acutely ill medical patients: need for trials in patients who are at high risk of venous thrombosis |
Q42757879 | Thromboprophylaxis for adults in hospital: Prophylaxis for medical inpatients is not entirely proven |
Q84340549 | Thromboprophylaxis in non-surgical cancer patients |
Q35630940 | Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis |
Q42281396 | Thrombotic risk assessment questionary helps increase the use of thromboprophylaxis for patients with pelvic and acetabular fractures |
Q38214961 | Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants |
Q30505527 | Unintended consequences of a standard admission order set on venous thromboembolism prophylaxis and patient outcomes |
Q35085954 | Use and outcomes of venous thromboembolism prophylaxis after spinal fusion surgery |
Q37740302 | VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients |
Q43154529 | Variation in physician deep vein thrombosis prophylaxis attitudes and practices at an academic tertiary care center |
Q51797008 | Venous thromboembolic events in hospitalised medical patients. |
Q53088997 | Venous thromboembolism and underutilisation of anticoagulant thromboprophylaxis in hospitalised patients with inflammatory bowel disease. |
Q37660669 | Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. |
Q33977588 | Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors |
Q92962824 | Venous thromboembolism incidence in the Ireland east hospital group: a retrospective 22-month observational study |
Q51733265 | Venous thromboembolism prevention in medical patients: a framework for improving practice. |
Q34825362 | Venous thromboembolism prophylaxis guideline implementation is improved by nurse directed feedback and audit |
Q44800823 | Venous thromboembolism prophylaxis in a general hospital |
Q42783150 | Venous thromboembolism prophylaxis in the United States: still room for improvement |
Q35442793 | Venous thromboprophylaxis in gastrointestinal bleeding |
Q57616393 | Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study |
Q83198043 | [Prophylaxis of venous thromboembolism: an unresolved matter?] |
Search more.